Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch

Max Gelman

Senior Editor

Microbiome pioneer Seres Therapeutics faced numerous setbacks throughout the years in numerous fields, most prominently for its lead program in C. difficile infections. But the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Plot­ting a come­back af­ter 2016 flop, Seres to raise $100M to prep C. dif­fi­cile pro­gram for launch

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration